CN100368398C - 3-氮杂二环(3.1.0)己烷衍生物作为类阿片受体拮抗剂 - Google Patents

3-氮杂二环(3.1.0)己烷衍生物作为类阿片受体拮抗剂 Download PDF

Info

Publication number
CN100368398C
CN100368398C CNB028208854A CN02820885A CN100368398C CN 100368398 C CN100368398 C CN 100368398C CN B028208854 A CNB028208854 A CN B028208854A CN 02820885 A CN02820885 A CN 02820885A CN 100368398 C CN100368398 C CN 100368398C
Authority
CN
China
Prior art keywords
aza
bicyclo
hex
ethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028208854A
Other languages
English (en)
Chinese (zh)
Other versions
CN1610664A (zh
Inventor
S·F·麦克哈迪
S·利拉斯
S·D·赫克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN1610664A publication Critical patent/CN1610664A/zh
Application granted granted Critical
Publication of CN100368398C publication Critical patent/CN100368398C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/04—Compounds containing oxirane rings containing only hydrogen and carbon atoms in addition to the ring oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNB028208854A 2001-10-22 2002-09-09 3-氮杂二环(3.1.0)己烷衍生物作为类阿片受体拮抗剂 Expired - Fee Related CN100368398C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33851101P 2001-10-22 2001-10-22
US60/338,511 2001-10-22

Publications (2)

Publication Number Publication Date
CN1610664A CN1610664A (zh) 2005-04-27
CN100368398C true CN100368398C (zh) 2008-02-13

Family

ID=23325099

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028208854A Expired - Fee Related CN100368398C (zh) 2001-10-22 2002-09-09 3-氮杂二环(3.1.0)己烷衍生物作为类阿片受体拮抗剂

Country Status (41)

Country Link
US (3) US7049335B2 (enExample)
EP (1) EP1440059B1 (enExample)
JP (2) JP4155522B2 (enExample)
KR (1) KR100621292B1 (enExample)
CN (1) CN100368398C (enExample)
AP (1) AP1816A (enExample)
AR (1) AR036905A1 (enExample)
AT (1) ATE392415T1 (enExample)
AU (1) AU2002329557B2 (enExample)
BR (1) BR0213464A (enExample)
CA (1) CA2463264C (enExample)
CR (1) CR7317A (enExample)
DE (1) DE60226161T2 (enExample)
DK (1) DK1440059T3 (enExample)
EA (1) EA006708B1 (enExample)
EC (1) ECSP045077A (enExample)
ES (1) ES2302839T3 (enExample)
GE (1) GEP20084300B (enExample)
GT (1) GT200200216A (enExample)
HN (1) HN2002000299A (enExample)
HR (1) HRP20040288A2 (enExample)
HU (1) HUP0401884A2 (enExample)
IL (2) IL161157A0 (enExample)
IS (1) IS7187A (enExample)
MA (1) MA27141A1 (enExample)
MX (1) MXPA04003730A (enExample)
MY (1) MY136580A (enExample)
NO (1) NO329092B1 (enExample)
NZ (1) NZ531807A (enExample)
OA (1) OA12711A (enExample)
PA (1) PA8556701A1 (enExample)
PE (1) PE20030610A1 (enExample)
PL (1) PL368919A1 (enExample)
PT (1) PT1440059E (enExample)
RS (1) RS25104A (enExample)
SI (1) SI1440059T1 (enExample)
SV (1) SV2004001363A (enExample)
TN (1) TNSN04071A1 (enExample)
UA (1) UA75714C2 (enExample)
WO (1) WO2003035622A1 (enExample)
ZA (1) ZA200402172B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428687A (zh) * 2015-05-20 2017-12-01 株式会社三和化学研究所 一种新型的3‑氮杂双环[3.1.0]己烷衍生物的盐的晶体以及其医药应用

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE434607T1 (de) 2001-04-18 2009-07-15 Euro Celtique Sa 1-(4-amino-cyclohexyl)-1,3-dihydro-2h- benzimidazole-2-on derivate und verwandte verbindungen als nociceptin analoge und orl1 liganden zur behandlung von schmerz
SI1440059T1 (sl) * 2001-10-22 2008-08-31 Pfizer Prod Inc Derivati 3-azabiciklo(3.1.0)heksana kot antagonisti opioidnega receptorja
CA2522323C (en) * 2003-04-14 2009-09-15 Pfizer Products Inc. 3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
US20050043327A1 (en) * 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) * 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound
AU2004281794B2 (en) * 2003-10-14 2010-04-22 Pfizer Products Inc. Bicyclic [3.1.0] derivatives as glycine transporter inhibitors
KR20060096038A (ko) * 2003-10-16 2006-09-05 화이자 프로덕츠 인크. 3-아자비시클로〔3.1.0〕헥산 유도체의 제조법
CA2557115C (en) 2004-02-23 2012-10-02 Glaxo Group Limited Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine d3 receptors
EP1726590A4 (en) * 2004-03-05 2009-07-15 Banyu Pharma Co Ltd CYCLOALKANOPYRIDINDERIVAT
CA2590182A1 (en) * 2004-12-14 2006-06-22 Shionogi & Co., Ltd. Indolomorphinan derivatives having carboxy at the 6'-position
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517191D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
US7592461B2 (en) * 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
MY145633A (en) 2006-03-01 2012-03-15 Theravance Inc 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2008075162A2 (en) * 2006-12-15 2008-06-26 Pfizer Limited Selective mu opioid receptor antagonists for the treatment of female sexual dysfunction
TWI409067B (zh) * 2007-02-28 2013-09-21 Theravance Inc ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型
WO2009029253A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Heteroarylalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2009029252A1 (en) * 2007-08-27 2009-03-05 Theravance, Inc. Amidoalkyl-8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
ATE502939T1 (de) * 2007-08-27 2011-04-15 Theravance Inc Disubstituierte alkyl-8-azabicycloä3.2.1üoktan- verbindungen als mu-opioid-rezeptorantagonisten
TWI423801B (zh) * 2007-08-27 2014-01-21 Theravance Inc 作為μ類鴉片受體拮抗劑之８－氮雜雙環〔３．２．１〕辛基－２－羥基苯甲醯胺化合物
US9133116B2 (en) 2010-09-28 2015-09-15 Panacea Biotec Ltd. Bicyclic compounds
WO2015076310A1 (ja) 2013-11-20 2015-05-28 株式会社 三和化学研究所 新規３－アザビシクロ［３．１．０］ヘキサン誘導体及びその医薬用途
AU2018229062A1 (en) 2017-03-02 2019-09-26 Ube Industries, Ltd. Therapeutic agent for alcohol use disorders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039089A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited 3-azabicyclo[3.1.0.] hexane derivatives as opiate receptors ligands

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2099214A (en) * 1937-11-16 Process fob forming the sulphuric
US2099216A (en) * 1934-05-04 1937-11-16 Frederick H Nass Metal testing machine
US3004340A (en) * 1959-09-24 1961-10-17 Bernice L Collins Kitchen utensil
US3078282A (en) * 1960-01-02 1963-02-19 Bayer Ag Anthraquinone dyestuffs
PH24752A (en) 1987-04-16 1990-10-01 Lilly Co Eli Piperidine opioid antagonists
JPH04155522A (ja) * 1990-10-19 1992-05-28 Nec Corp ファースト・イン・ランダム・アウト回路
ZA922180B (en) 1991-03-29 1993-09-27 Lilly Co Eli Piperidine derivatives
US5159081A (en) 1991-03-29 1992-10-27 Eli Lilly And Company Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists
GB9725114D0 (en) * 1997-11-28 1998-01-28 Pfizer Ltd Treatment of pruritus
GB9810671D0 (en) 1998-05-18 1998-07-15 Pfizer Ltd Anti-pruritic agents
GB9912410D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912411D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912415D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
GB9912413D0 (en) * 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
US20020064825A1 (en) 2000-05-19 2002-05-30 Lewis Marilyn Evelyn Novel polypeptide
US20020025948A1 (en) * 2000-06-23 2002-02-28 Banks Bernard Joseph 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
US20030207876A1 (en) * 2000-06-23 2003-11-06 Banks Bernard Joseph 3-Azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0015562D0 (en) * 2000-06-23 2000-08-16 Pfizer Ltd Heterocycles
DE10042885A1 (de) * 2000-08-31 2002-03-14 Heidelberger Druckmasch Ag Bogentransportzylinder
SI1440059T1 (sl) 2001-10-22 2008-08-31 Pfizer Prod Inc Derivati 3-azabiciklo(3.1.0)heksana kot antagonisti opioidnega receptorja
WO2003101963A1 (en) 2002-05-30 2003-12-11 Eli Lilly And Company Opioid receptor antagonists
US20040204453A1 (en) 2003-04-14 2004-10-14 Pfizer Inc 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
US7056930B2 (en) 2003-04-14 2006-06-06 Pfizer Inc. 2-Azabicyclo[3.3.1]nonane derivatives
US20050043327A1 (en) 2003-08-21 2005-02-24 Pfizer Inc Pharmaceutical composition for the prevention and treatment of addiction in a mammal
US7153976B2 (en) 2003-10-06 2006-12-26 Pfizer Inc. Purification process for an azabicyclo[3.1.0]hexane compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000039089A1 (en) * 1998-12-23 2000-07-06 Pfizer Limited 3-azabicyclo[3.1.0.] hexane derivatives as opiate receptors ligands

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Chemistry of Ehtylenimine. VI. Pyrolysis of7-acetyl-7-azaspiro[5.2]octane. TALUKDAR PB ET AT.JOURNAL OF ORGANIC CHEMISTRY,Vol.24 No... 1959 *
New alkamines in the tetrahydronaphthalene series. MOSETTIG E ET AL.JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,Vol.53 No... 1931 *
PREPARATION OF TETRAHYDROBENZCDINDOLESFROM 1-TETRALONES. BECK A L ET AL.JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1,Vol.- No... 1990 *
Ring enlargement with diazomethane in thehydro-aromaticseries. MOSETTIG E ET AL.JOURNAL OF THE AMERICAN CHEMICAL SOCIETY,Vol.52 No... 1930 *
Spiroheterocycles derived from tetralone. CAMPBELL M M ET AL.TETRAHEDRON,Vol.41 No.23. 1985 *
The use of alpha-amino acids in the synthesis of Derivativesof 2-aminoethanethiol as potential antiradiation agents. PIPER J R.JOURNAL OF MEDICINAL CHEMISTRY,Vol.9 No... 1966 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107428687A (zh) * 2015-05-20 2017-12-01 株式会社三和化学研究所 一种新型的3‑氮杂双环[3.1.0]己烷衍生物的盐的晶体以及其医药应用
CN107428687B (zh) * 2015-05-20 2021-06-11 宇部兴产株式会社 一种3-氮杂双环[3.1.0]己烷衍生物的盐的晶体以及其医药应用

Also Published As

Publication number Publication date
MY136580A (en) 2008-10-31
US7049335B2 (en) 2006-05-23
WO2003035622A1 (en) 2003-05-01
CN1610664A (zh) 2005-04-27
BR0213464A (pt) 2004-11-09
UA75714C2 (en) 2006-05-15
SV2004001363A (es) 2004-02-24
US20030087898A1 (en) 2003-05-08
PE20030610A1 (es) 2003-07-12
JP4155522B2 (ja) 2008-09-24
JP2005511545A (ja) 2005-04-28
SI1440059T1 (sl) 2008-08-31
EA200400467A1 (ru) 2004-08-26
GT200200216A (es) 2003-05-23
US20050171178A1 (en) 2005-08-04
IS7187A (is) 2004-03-18
AP1816A (en) 2008-01-04
HN2002000299A (es) 2002-11-21
DE60226161D1 (de) 2008-05-29
DE60226161T2 (de) 2009-07-02
ECSP045077A (es) 2004-05-28
IL161157A0 (en) 2004-08-31
TNSN04071A1 (fr) 2006-06-01
MXPA04003730A (es) 2004-07-23
ES2302839T3 (es) 2008-08-01
PA8556701A1 (es) 2003-07-28
OA12711A (en) 2006-06-27
RS25104A (sr) 2007-02-05
HUP0401884A2 (hu) 2005-01-28
CA2463264A1 (en) 2003-05-01
EA006708B1 (ru) 2006-02-24
CA2463264C (en) 2009-05-26
NZ531807A (en) 2006-03-31
GEP20084300B (en) 2008-02-11
PT1440059E (pt) 2008-05-16
HK1072052A1 (zh) 2005-08-12
EP1440059B1 (en) 2008-04-16
MA27141A1 (fr) 2005-01-03
PL368919A1 (en) 2005-04-04
AU2002329557B2 (en) 2008-07-31
AP2004003007A0 (en) 2004-06-30
KR100621292B1 (ko) 2006-09-13
ZA200402172B (en) 2006-09-27
JP2008069169A (ja) 2008-03-27
NO329092B1 (no) 2010-08-23
ATE392415T1 (de) 2008-05-15
HRP20040288A2 (en) 2004-12-31
AR036905A1 (es) 2004-10-13
CR7317A (es) 2006-08-09
EP1440059A1 (en) 2004-07-28
KR20040048984A (ko) 2004-06-10
NO20041626L (no) 2004-05-26
IL161157A (en) 2009-09-01
DK1440059T3 (da) 2008-07-14
US20070054950A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
CN100368398C (zh) 3-氮杂二环(3.1.0)己烷衍生物作为类阿片受体拮抗剂
AU2002329557A1 (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
USRE40838E1 (en) 2-azabicyclo[3.3.1]nonane derivatives
JP5291623B2 (ja) 新規化合物
KR20160098506A (ko) 통증에 대한 다양한 활성을 갖는 피페라진 유도체
JP2006522792A (ja) ４−フェニル−ピペリジン化合物およびそのオピオイド受容体のモジュレーターとしての使用
RU2136678C1 (ru) Производные n-замещенного 3-азабицикло[3.2.0]гептана
WO2004089908A2 (en) 3-azabicyclo[3.2.1]octane derivatives
US7560479B2 (en) 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
HK1072052B (en) 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists
TW200526578A (en) Process for preparing an azabicyclo[3.1.0]hexane compound
JPH08509491A (ja) 胃腸疾患の治療に有用なエタノールアミン誘導体
WO2024002379A1 (zh) 一种用作wdr5抑制剂的化合物或其可药用盐及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1072052

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1072052

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080213

Termination date: 20110909